MaxCyte is a cell-engineering company that provides technologies to support the development of cell-based therapeutics, from discovery to commercialization. They focus on enabling non-viral cell engineering using their Flow Electroporation® technology, which allows for the efficient and scalable modification of cells.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?